Emily Colman is Co-Founder and COO at RonanRx, an AI-powered platform delivering personalized, doctor-reviewed peptide and GLP-1 care that starts with a text.

Emily spent nearly a decade in healthcare sales, most recently at Eli Lilly, where she supported weight-management solutions for hundreds of physicians and millions of patients.

Emily brings a rare combination of deep healthcare industry knowledge and go-to-market expertise to a space long overdue for personalization and patient-first innovation.

As COO, Emily leads operations and commercialization at RonanRx, a Y Combinator Summer 2026 company whose founding team has collectively raised over $100M and built a $50M U.S. medical manufacturing business.

RonanRx has built a complete feedback loop for personalized medicine, continuously adapting GLP-1 and peptide treatments to each patient's evolving biology using labs, wearables, and medical history.